Seattle's success with Adcetris could spark more antibody-drug conjugates investment
This article was originally published in Scrip
Executive Summary
With an FDA panel unanimously recommending accelerated approval for Adcetris for relapsed/refractory Hodgkin's lymphoma and relapsed/refractory systemic anaplastic large cell lymphoma - and with treatment options for these indications limited - commercial success for the drug could attract further investment in antibody-drug conjugate (ADC) technologies.